Karam C. Mounzer - Faculty Biosketch

Karam C. Mounzer, MD

Clinical Professor of Medicine (Infectious Diseases)

Attending Physician, Penn Presbyterian Medical Center

3 5f

Department: Medicine

4 1 b

46 Contact information
40

Philadelphia Fight
35 1233 Locust Street
Philadelphia, PA 19107

2e Office: 215-790-1788
32 Fax: 215-732-5490
24

Email:
mounzerk@fight.org

4 3 3 3 2 29

Links
59 AIDS service organization
c

4 b 1f

13 Education:
21 d Bachelor 38 (Experimental Sciences and French Literature) c
47 College Notre Dame de Jamhour, Beirut, Lebanon, 1985.
21 7 MD 23 (Pre-Med & Med combined) c
57 Saint Joseph University, Faculty of Medicine, Beirut, Lebanon , 1992.
c

3 3 21

1f Post-Graduate Training
24 87 Internal Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 1992-1993.
24 66 Residency, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School 1b , 1993-1995.
24 7b Infectious Diseases Fellowship, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School 1b , 1995-1997.
c

3 25

17 Certifications
28 34 Diplomate, American Board of Internal Medicine 16 , 1995.
28 35 Diplomate, American Board of Infectious Diseases 16 , 1997.
28 2f ABIM Internal Medicine, 2015.
c

3 8b Permanent link
2 29

b6 > Perelman School of Medicine > Faculty > Details a

1e 1d

Description of Research Expertise

41 Clinical Development of new antiretroviral agents
65

Description of Clinical Expertise

51 Treatment of Multi drug Resistant HIV virus, HIV-HCV co-infection
62

Description of Other Expertise

49 Suboxone Clinic for HIV infected opioid-addicted patients
e 29

Selected Publications

7a Dieterich DT, Brunet L, Hsu RK, Mounzer K, Pierone G Jr, Wohlfeiler MB, Fusco 4b JS, Dunbar MS, Gruber J, Yee LJ, Frenette C, Lim T, Fusco GP. 1c : . Monitoring and 86 risk of hepatitis B reactivation and hepatitis flare during tenofovir interruption among people with HIV and hepatitis B. 27 AIDS Jan 2026.

3a Isobel McEwen1 15 , Gayathri Sridhar2 12 , Richard Elion1 11 , Leigh Ragone3 f , Annemiek De 9 Ruiter2 12 , Michael Aboud2 11 , Jean van Wyk4 12 , Kenneth Mayer5 12 , Karam Mounzer6 8 , Moti e N. Ramgopal7 67 , Vani Vannappagari2: Long-Term Use, HIV Testing & Effectiveness in Individuals on CAB LA PrEP 42 in the Trio Health Cohort. CROI 2026 2026.

3c Laurence Brunet1 16 , Steven K. Barnett2 13 , Jennifer Fusco3 12 , Karam Mounzer4 3 , 11 Kevin R. Frost5 13 , Supriya Sarkar6 14 , Kimberley Brown7 16 , Harmony P. Garges7 8 , Vani f Vannappagari7 61 , Gregory P. Fusco3: Comparing PrEP Coverage and HIV Acquisition Between CAB LA and Oral 41 PrEP in the OPERA Cohort. CROI 2026 2026.

41 Douglas T. Dieterich1 14 , Laurence Brunet2 11 , Ricky K. Hsu3 12 , Karam Mounzer4 a , Gerald a Pierone5 1a , Michael B. Wohlfeiler6 14 , Rachel P. Weber7 13 , Jennifer Fusco7 b , Cassidy a Henegar8 16 , Vani Vannappagari9 14 , Kimberley Brown9 15 , Nassrin Payvandi8 b , Gregory 59 P. Fusco7: HIV-HBV Coinfection and Long-Acting Cabotegravir + Rilpivirine in the 41 US: HBV and HIV Outcomes. CROI 2026 2026.

3d Malcolm Hedgcock1 f , Mark Bloch2 f , Jihad Slim3 15 , Moti N. Ramgopal4 c , Jorge L. a Santana5 d , Xu Zhang6 1d , Jairo M. Montezuma-Rusca6 10 , Peter Sklar6 5b , Karam Mounzer7: Switch to BIC+LEN in Virologically Suppressed People With HIV on 4b Complex Regimens: Week 96 Outcomes. CROI 2026 2026.

3d Mohammed Zogheib1 10 , John Koethe2 12 , Karam Mounzer3 11 , John J. Carr2 c , James G. 8 Terry2 12 , Sangeeta Nair2 10 , Jordan Lake4 63 , Colleen McGary1: Presence of Excess Visceral Abdominal Fat Impacts MASLD in People With 2c HIV. CROI 2026 2026.

3c Laurence Brunet1 11 , Ricky K. Hsu2 12 , Anthony Mills3 13 , Kevin R. Frost4 13 , Gerald Pierone5 3 , 12 Michael Sension6 15 , Philip C. Lackey7 12 , Karam Mounzer8 1a , Michael B. Wohlfeiler9 3 , 4e Jennifer Fusco10, Michael Aboud11, Piotr Budnik12, Adrienne Guignard13, Vani a3 Vannappagari11, Gregory P. Fusco10: Cabotegravir LA for PrEP: Progress in HIV Prevention From 3 Years of OPERA Data CROI 2026 2026.

3b Chloe M. Orkin1 13 , Peter J. Ruane2 15 , Malcolm Hedgcock3 13 , Cyril Gaultier4 b , Marcelo 8 Losso5 f , Mark Bloch6 12 , Karam Mounzer7 13 , Hung-Chin Tsai8 11 , Kwanza Price9 9 , Keith 8 Aizen9 10 , Martin Rhee9 d , Xu Zhang9 1d , Jairo M. Montezuma-Rusca9 10 , Peter Sklar9 9 , Pedro 50 Cahn10: Phase III Efficacy and Safety of Switch From Complex Regimen to 4c Single-Tablet BIC/LEN in ARTISTRY-1. CROI 2026 2026.

70 . Wei Y, Ma HK, Wong ME, Back H, Papasavvas E, Mounzer K, Aberra F, 48 Morgenstern R , Tebas P, Konnikova L, Montaner LJ, Ho YC. 73 : Transcription factor BACH2 shapes tissue-resident memory T cell programs to promote HIV-1 persistence. I 2b Immunity Nov 2025.

76 . Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Aizen K, 41 Zhang X, Sklar P, Montezuma-Rusca JM, Segal-Maurer S b8 : . Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. 1c Open Forum Infect Dis 1e Oct 2025.

2c

7 1d

2c back to top
26 Last updated: 03/01/2026
34 The Trustees of the University of Pennsylvania c